-
公开(公告)号：US20090136528A1
公开(公告)日：2009-05-28
申请号：US12180045
申请日：2008-07-25
申请人： Harpreet SINGH , Steffen WALTER , Toni WEINSCHENK , Norbert HILF , Oliver Schoor , Claudia Lemmel
发明人： Harpreet SINGH , Steffen WALTER , Toni WEINSCHENK , Norbert HILF , Oliver Schoor , Claudia Lemmel
IPC分类号： A61K39/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07H21/00 , C12N15/63 , A61P35/00 , C12N5/00 , C12P21/00 , C12N5/08 , A61K35/12
CPC分类号： A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/572 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C07K2317/34 , C07K2319/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , C12N2502/1157 , C12Y208/02011
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses.
摘要翻译： 本发明涉及用于免疫治疗方法的肽，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及肿瘤相关的T辅助细胞肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽组合。 本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的HLA I类和II类分子的新型肽序列及其变体。
-
公开(公告)号：US20130004456A1
公开(公告)日：2013-01-03
申请号：US13588206
申请日：2012-08-17
申请人： Toni WEINSCHENK , Oliver SCHOOR , Claudia TRAUTWEIN , Norbert HILF , Steffen WALTER , Harpreet SINGH
发明人： Toni WEINSCHENK , Oliver SCHOOR , Claudia TRAUTWEIN , Norbert HILF , Steffen WALTER , Harpreet SINGH
CPC分类号： C07K7/06 , A61K35/17 , A61K38/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/572 , A61K2039/605 , A61K2039/6081 , A61K2039/6093 , A61M5/002 , C07K7/08 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C12N5/0638 , C12N2501/50 , G01N33/57492 , Y02A50/472
摘要： The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas.
-
公开(公告)号：US20110229505A1
公开(公告)日：2011-09-22
申请号：US13051701
申请日：2011-03-18
申请人： Jens FRITSCHE , Toni WEINSCHENK , Steffen WALTER , Peter LEWANDROWSKI , Harpreet SINGH , Oliver SCHOOR
发明人： Jens FRITSCHE , Toni WEINSCHENK , Steffen WALTER , Peter LEWANDROWSKI , Harpreet SINGH , Oliver SCHOOR
IPC分类号： A61K39/00 , C12N15/63 , C12N5/0783 , C12N5/10 , C12N1/00 , C12Q1/68 , G01N33/574 , C07K14/47 , C07K7/06 , C07K7/08 , C07K19/00 , C07H21/00 , A61K38/17 , C07K16/18 , A61K48/00 , A61K35/00 , A61P35/00 , A61P37/04
CPC分类号： A61K38/1709 , A61K39/0011 , C07K14/4748 , G01N33/57492 , G01N2800/52 , G01N2800/56
摘要： The present invention relates to methods for the diagnosis and treatment of cancer in mammals, in particular gastric cancer, based on the new target AVL9. The present invention thus relates to diagnostic methods and related components to be used in such methods. Furthermore, the present invention relates to the treatment of cancer in mammals, in particular gastric cancer, based on AVL9 as a target. Specifically, the present invention relates to the immunotherapy of cancer using AVL9 tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides, and respective pharmaceutical compositions, in particular vaccine compositions.
摘要翻译： 本发明涉及基于新靶标AVL9来诊断和治疗哺乳动物癌症，特别是胃癌的方法。 因此，本发明涉及用于这些方法的诊断方法和相关组件。 此外，本发明涉及以AVL9为靶标的哺乳动物癌症，特别是胃癌的治疗。 具体地，本发明涉及使用AVL9肿瘤相关的细胞毒性T细胞（CTL）肽表位的癌症的免疫治疗，其单独或与其它肿瘤相关肽组合，以及各自的药物组合物，特别是疫苗组合物。
-
4.发明申请Novel immunotherapy against several tumors including gastrointestinal and gastric cancer 有权对几种肿瘤的新型免疫治疗，包括胃肠和胃癌公开(公告)号：US20110229504A1
公开(公告)日：2011-09-22
申请号：US13051665
申请日：2011-03-18
IPC分类号： A61K39/00 , C07K7/06 , C07H21/02 , C07H21/04 , C12N15/63 , C12N5/10 , C12P21/02 , C12N5/0783 , A61K35/12 , A61K31/7088 , A61P35/00 , A61P37/04
CPC分类号： A61K38/1709 , A61K39/0011 , A61K2039/5158 , A61K2039/572 , A61K2039/585 , A61P35/00 , C07K7/06 , C07K2319/00 , G01N33/505
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
摘要翻译： 本发明涉及用于免疫治疗方法的肽，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及肿瘤相关的细胞毒性T细胞（CTL）肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽的组合。 本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的95种新型肽序列及其衍生自人类肿瘤细胞HLA I类分子的变体。
-
5.发明申请CANCER THERAPY BASED ON TUMOR ASSOCIATED ANTIGENS DERIVED FROM CYCLIN D1 有权基于从CYCLIN D1衍生的肿瘤相关抗原的癌症治疗公开(公告)号：US20120027684A1
公开(公告)日：2012-02-02
申请号：US13150785
申请日：2011-06-01
申请人： Harpreet SINGH , Toni WEINSCHENK , Steffen WALTER
发明人： Harpreet SINGH , Toni WEINSCHENK , Steffen WALTER
IPC分类号： A61K38/10 , C07K7/08 , A61K38/08 , A61K39/00 , A61P35/02 , C12N5/0783 , A61K49/00 , C07K7/06 , A61P35/00
CPC分类号： A61K39/0011 , A61K31/404 , A61K31/44 , A61K31/675 , A61K38/1709 , A61K38/193 , A61K38/20 , A61K38/2013 , A61K38/2026 , A61K38/21 , A61K39/39 , A61K45/06 , C07K14/4738 , C12N5/0638 , G01N2800/24 , G01N2800/7028 , A61K2300/00
摘要： The present invention relates to cyclin D1-derived peptides for use in the improved treatment of cancer in a patient, particularly in the form of a combination therapy using a vaccine. Other aspects relate to the use of the peptides or a combination thereof as a diagnostic tool.
摘要翻译： 本发明涉及用于改善患者癌症治疗的细胞周期蛋白D1衍生肽，特别是以使用疫苗的组合疗法的形式。 其他方面涉及肽或其组合的用途作为诊断工具。
-
6.发明申请公开(公告)号：US20110229524A1
公开(公告)日：2011-09-22
申请号：US13051568
申请日：2011-03-18
IPC分类号： A61K39/00 , A61K47/02 , A61P35/00 , A61K47/06 , A61K38/10 , A61K38/08 , A61K31/7088 , A61K47/42
CPC分类号： A61K39/0011 , A61K2039/55511 , A61K2039/55522 , C07K14/4748
摘要： The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gastric cancers (GC).
摘要翻译： 本发明涉及免疫治疗肽及其在免疫治疗中的用途，特别是癌症的免疫治疗。 本发明公开了肿瘤相关的T辅助细胞肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽组合。 特别地，本发明的肽的组合物可用于引发针对胃癌（GC）的抗肿瘤免疫应答的疫苗组合物中。
-
7.发明申请公开(公告)号：US20120128702A1
公开(公告)日：2012-05-24
申请号：US13302674
申请日：2011-11-22
申请人： Toni WEINSCHENK , Harpreet SINGH , Andrea MAHR , Jens FRITSCHE
发明人： Toni WEINSCHENK , Harpreet SINGH , Andrea MAHR , Jens FRITSCHE
CPC分类号： G01N33/57488 , G01N33/5011 , G01N33/574 , G01N2333/523 , G01N2333/775 , G01N2800/52
摘要： The present invention relates to methods for predicting the effect of an immunotherapy against cancer in a patient based on new biomarkers. The present invention furthermore relates to a prognosis regarding the outcome based on said biomarkers. The present invention furthermore relates to panels of biomarkers for use in the above methods.
摘要翻译： 本发明涉及用于基于新的生物标志物预测患者中针对癌症的免疫治疗效果的方法。 本发明还涉及关于基于所述生物标志物的结果的预后。 本发明还涉及用于上述方法的生物标志物组。
-
公开(公告)号：US20120070461A1
公开(公告)日：2012-03-22
申请号：US13239011
申请日：2011-09-21
CPC分类号： G01N33/57419 , G01N33/5047 , G01N33/5743 , G01N33/57438 , G01N33/57446
摘要： The present invention relates to the use of myeloid cell biomarkers for the differential diagnosis, prognosis, and monitoring of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to monitoring the effect of a treatment against renal cell carcinoma (RCC) or colorectal cancer (CRC), and establishing a prognosis of the outcome of the treatment of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to panels of cellular biomarkers for use in the above methods, in particular multicolor panels for measuring said biomarkers.
摘要翻译： 本发明涉及骨髓细胞生物标志物用于肾细胞癌（RCC）或结肠直肠癌（CRC）的鉴别诊断，预后和监测的用途。 本发明还涉及监测针对肾细胞癌（RCC）或结肠直肠癌（CRC）的治疗效果，以及建立肾细胞癌（RCC）或结肠直肠癌（CRC）治疗结果的预后。 本发明还涉及用于上述方法的细胞生物标志物的面板，特别是用于测量所述生物标志物的多色面板。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.035 秒)
